THIRD U.S. PATENT AWARDED TO ENADA - NADH
A NUTRITIONAL SUPPLEMENT OFFERING RELIEF FOR
CHRONIC FATIGUE SYNDROME (CFS)
NEW YORK, N.Y, - MENUCO CORPORATION AND BIRKMAYER PHARMACEUTICALS patent holders for the nutritional supplement ENADA have been awarded a third U.S. patent regarding ENADA NADH'S usage for Chronic Fatigue Syndrome relief. A double-blind, placebo-controlled clinical study conducted at Georgetown University Medical Center found that ENADA - the only stabilized, absorbable oral form of the coenzyme NADH was four times more effective in relieving the symptoms of CFS versus placebo. The 3 month study included four weeks on 10 mg. of ENADA or a placebo, four weeks off any medication, and then four weeks on 10 mg. of ENADA or placebo.
Additionally in a follow-up open-label study, 73% of the patients achieved marked improvement over time. Researchers identified no adverse effects from taking ENADA and no interactions with antidepressants or antihistamines.
The usage patent was issued by the United States Patent and Trademark Office on January 27,1998, Patent No. 5,712,259. Together with this patent, Birkmayer Pharmaceuticals holds over 30 worldwide patents for other applications of stabilized NADH. Applications include all oral, sublingual, nasal spray, dermal as well as rectal. Birkmayer Pharmaceuticals and Menuco continue to vigorously defend their ENADA NADH patents against all infringements.
Wizards Gate is dedicated to bringing this valuable supplement to you at the lowest possible prices, and FREE Priority Mail Shipping when ordering two or more of any size ENADA®
To order ENADA® NADH The Energizing Coenzyme, click below